



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 52589

**Title:** The role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer

**Reviewer's code:** 03731607

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Assistant Professor, Surgical Oncologist

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-03-04

**Reviewer chosen by:** Jie Wang

**Reviewer accepted review:** 2020-03-14 13:07

**Reviewer performed review:** 2020-03-15 01:19

**Review time:** 12 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## **SPECIFIC COMMENTS TO AUTHORS**

The authors present a case control study evaluating adjuvant HIPEC for locally advanced gastric cancer. They report fewer peritoneal recurrences, improved disease-free and overall survival with the addition of HIPEC. This study adds to the growing body of evidence suggesting an improvement in outcomes with adjuvant HIPEC without increasing complications. The GASTRICHIP trial will hopefully answer this question. The manuscript needs significant language editing and polishing to make it more fluid and readable. I also have the following suggestions for improvement

- 1) I am confused. Is this a prospective registry or observational study? Was all data collected prospectively? How was treatment arm assigned? This needs more explanation.
- 2) please add the p-values to the Kaplan-Meier graphs
- 3) please add a row below the Kaplan Meier graphs with the number at risk at each time point
- 4) in the tables can the authors please report absolute number and percentage of the total
- 5) can the authors give more clarity to how all patients were staged? Did they all get PET, CT, EUS and diagnostic laparoscopy with peritoneal cytology?
- 6) can the authors add what chemotherapeutic agents and dosage they used for the HIPEC?
- 7) the authors need to include the upcoming GASTRICHIP trial in their discussion
- 8) the inclusion/exclusion criteria is very poorly written and needs to be revised to make it more clear how patients were chosen for the study
- 9) were all the operations done open or were some done MIS?
- 10) peritoneal recurrence should be reported as a time-to-event analysis. So peritoneal recurrence-free survival.
- 11) complications should be reported using Clavien-Dindo classification or using the common terminology criteria for adverse events (CTCAE). They should also be reported for either 30, 60 or 90 days and this should all be outlined in the methods. Mortality should also be reported as 30, 60, or 90 days.
- 12) authors may want to add margin status to table 1



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 52589

**Title:** The role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer

**Reviewer's code:** 02855696

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Associate Professor, Professor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-03-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-03-09 01:22

**Reviewer performed review:** 2020-03-19 01:16

**Review time:** 9 Days and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This study is very interesting. In this study, the role of preventive hyperthermic intraperitoneal perfusion after radical gastrectomy was studied. The design of the study is overall good, and the manuscript is acceptable. Comments: 1. The manuscript requires an editing. A minor language polishing should be corrected. 2. The inclusion/exclusion criteria is not in detail, please check and revise. 3. Discussion is interesting.



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 52589

**Title:** The role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer

**Reviewer's code:** 02992560

**Position:** Peer Reviewer

**Academic degree:** FACC, MD, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Germany

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-03-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-03-09 01:21

**Reviewer performed review:** 2020-03-19 01:37

**Review time:** 10 Days

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

Very interesting study. I recommend to accept this manuscript after a minor language editing. Authors should give more clarity to how all patients were staged, and how about the PET, CT, EUS and diagnostic laparoscopy with peritoneal cytology?